|
EP1663299A2
|
|
Methods for preventing neurological events
|
|
EP1603601A1
|
|
Coating composition for polymeric surfaces comprising serpin or serpin derivatives
|
|
US2005032745A1
|
|
Modified low molecular weight heparin that inhibits clot associated coagulation factors
|
|
ZA200110525B
|
|
Heparin compositions that inhibit clot associated coagulation factors.
|
|
WO0220091A2
|
|
Antithrombotic compositions
|
|
US2001046974A1
|
|
Modified low molecular weight heparin that inhibits clot associated coagulation factors
|
|
AU1683801A
|
|
Methods and compositions for modulating er-stress-induced cholesterol/triglyceride accumulation
|
|
EP1192187A1
|
|
Heparin compositions that inhibit clot associated coagulation factors
|
|
EP1079847A2
|
|
Osteoporosis treatment
|
|
EP0986581A1
|
|
Modified low molecular weight heparin that inhibits clot associated coagulation factors
|
|
US6001820A
|
|
Compositions and methods for inhibiting thrombogenesis
|
|
US6491965B1
|
|
Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
|
|
US5767269A
|
|
Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
|
|
GB9606881D0
|
|
Compositions for inhibiting thrombogenesis
|
|
US5763427A
|
|
Compositions and methods for inhibiting thrombogenesis
|
|
US5817461A
|
|
Methods and compositions for diagnosis of hyperhomocysteinemia
|
|
US6562781B1
|
|
Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
|
|
US5744457A
|
|
Compositions and methods for inhibiting thrombogenesis
|
|
WO9530438A2
|
|
Methods and compositions to enhance endogenous fibrinolytic activity
|
|
US5643192A
|
|
Autologous fibrin glue and methods for its preparation and use
|
